Pre-earnings options volume in Pac Bio is 1.8x normal with calls leading puts 9:4. Implied volatility suggests the market is anticipating a move near 14.7%, or 36c, after results are released. Median move over the past eight quarters is 7.6%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Pacific Biosciences (PACB) Q3 Earnings Cheat Sheet
- PacBio announces SPRQ chemistry for Revio sequencing systems
- PacBio includes Onso platform in 10x Genomics Compatible Partner Program
- Tesla lower after ‘underwhelming’ robotaxi launch event: Morning Buzz
- PacBio enters research collaboration with National Cancer Centre of Singapore